A side-by-side comparison of two Healthcare investors: Perceptive Advisors (Power Score 82/100) and Vivo Capital (Power Score 83/100), both ranked among the most active firms tracked in this category.
| Perceptive Advisors | Vivo Capital | |
|---|---|---|
| Power Score™ | 82/100 | 83/100 |
| Assets Managed | Approximately $11B (across its strategies as of 30 June 2026, per the firm's own About page; the firm's Form ADV Item 5.F figure could not be read) | $6.1B ("Active AUM" as of Q4 2025, the label the firm uses on its own homepage; it separately stated approximately $5.3B of regulatory assets under management in its 7 May 2025 fund-close announcement) |
| Founded | 1999 | 1996 |
| Headquarters | New York, NY | Palo Alto, CA |
| Sectors | Biotech, Life Sciences, Medical Devices, Diagnostics, Digital Health, Healthcare IT | Healthcare, Biotech, Pharmaceuticals, Life Sciences, Healthtech |
Perceptive Advisors is a life sciences investment manager registered with the SEC as an investment adviser (CRD 154703, SEC registration effective 4 October 2010). It says it runs four strategies. The Perceptive Life Sciences Fund invests globally in public and private companies developing biotechnology products, drugs, medical devices and diagnostics, with the majority of investments in publicly traded small and mid cap companies, and participates in growth rounds, crossover rounds, IPOs and public follow-ons. Credit Opportunities, launched with its first closed-end fund in 2014, lends to healthcare companies across biopharma, medical devices, diagnostics, digital health, women's health, life sciences research and healthcare IT, and states a range of $20M to $300M per investment and approximately $3.5B of capital raised for private credit. Capital Solutions provides structured capital to later-stage and commercial-stage life sciences companies. The venture strategy, run through the Perceptive Xontogeny Venture Funds, invests primarily at seed and Series A in biotechnology, medtech, healthtech, digital health and healthcare tools and services, states investments of $10M to $50M when leading or co-leading a Series A, states over $700M across its venture funds, and says its people take board seats. The firm describes its team as scientists, technologists, molecular biologists, MDs and PhDs.
View full Perceptive Advisors profile →Vivo Capital describes itself as a global healthcare specialist running a multi-strategy investment platform that covers venture capital, private equity and public equity. Its investment strategy page names three distinct strategies: the Vivo Innovation Fund, which invests in venture-stage companies developing healthcare technologies or products; Vivo Capital Private Equity, which combines growth capital for companies at commercial inflection points with a buyout strategy covering leveraged buyouts, management buyouts, spin-offs and restructurings; and the Vivo Opportunity Fund, a long-only strategy investing primarily in global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies through follow-ons, PIPEs, registered directs and IPOs. The firm states it has invested in over 460 healthcare companies and operates from Palo Alto with offices in China and a presence in Singapore.
View full Vivo Capital profile →